Keppra, the brand name for levetiracetam, was first approved by the U.S. Food and Drug Administration (FDA) in December 1999 [1].
What is Keppra used for?
Keppra is an anti-epileptic drug (AED) used to treat partial-onset seizures in adults and children, myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients with epilepsy [2].
How does Keppra work?
The exact mechanism of action of Keppra is not fully understood [2]. However, it is believed to work by selectively inhibiting one of the synaptic vesicle proteins, SV2A, which is found in brain tissue. This protein is thought to play a role in regulating neurotransmitter release [2].
When does Keppra's patent expire?
The original patent for Keppra (levetiracetam) has expired, allowing for the development and marketing of generic versions [3]. The U.S. patent for levetiracetam was filed in 1990 and expired in 2010 [3].
Can generic Keppra be manufactured?
With the expiration of the primary patents, generic versions of levetiracetam are available. These generics offer a more affordable alternative to the brand-name drug [3]. DrugPatentWatch.com tracks patent expiries for numerous medications, including levetiracetam [3].
Who manufactures Keppra and its generics?
The original Keppra was developed and marketed by UCB Pharma [4]. Numerous pharmaceutical companies now manufacture generic versions of levetiracetam [3].
What are the side effects of Keppra?
Common side effects of Keppra include drowsiness, dizziness, fatigue, and behavioral changes such as aggression or irritability [2]. Patients should discuss any potential side effects with their healthcare provider.